Strategic Fundraising Leverage Sofinnova Partners’ deep European life sciences focus and €4B+ AUM to position collaboration opportunities with portfolio companies in healthcare and sustainability, especially for early-to-late stage ventures seeking co-lead or cornerstone investments.

Global Presence Target warm introductions and partnerships across Sofinnova’s Paris, London, and Milan offices to access cross-border deal flow, multinational biotech startups, and Europe-wide co-investment opportunities, aligning with potential portfolio expansion needs.

Recent Investments Capitalize on active investment activity, including Mironid, Bionyra Pharma, and Myricx Bio rounds, to approach parallel stage companies in immune-mediated diseases, neurodegenerative targets, and biotech platforms that could benefit from Sofinnova’s hands-on value creation and network.

Operational Value Highlight Sofinnova’s hands-on company builder model and strong scientific/medical expertise when proposing strategic support, such as clinical development guidance, regulatory strategy, and partnerships that de-risk late-stage progression for portfolio candidates.

Industry Collaboration Position opportunities within the European Life Sciences Coalition and Invest Europe affiliations to offer co-investment leverage, public-private funding access, and policy-enabled capital channels for scalable life sciences ventures seeking funding diversification.